Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome

YILMAZ, SONGÜL; ÖZÇAKAR, ZEYNEP; Taktak, Aysel; KİREMİTCİ, SABA; ENSARİ, ARZU; DİNÇASLAN, HANDAN; Yalcinkaya, Fatos

doi:10.1007/s00467-016-3355-z

Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome

YILMAZ S., ÖZÇAKAR Z. B., Taktak A., KİREMİTCİ S., ENSARİ A., DİNÇASLAN H., ...Daha Fazla

PEDIATRIC NEPHROLOGY, cilt.31, sa.6, ss.1029-1032, 2016 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 31 Sayı: 6
Basım Tarihi: 2016
Doi Numarası: 10.1007/s00467-016-3355-z
Dergi Adı: PEDIATRIC NEPHROLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1029-1032
Anahtar Kelimeler: Thrombotic microangiopathy, Bevacizumab, Anti-VEGF, Nephrotic syndrome, Child, TARGETED THERAPY, BEVACIZUMAB, ANGIOGENESIS, INHIBITION, SORAFENIB, TOXICITY
Ankara Üniversitesi Adresli: Evet

Özet

Targeting the vascular endothelial growth factor (VEGF) signaling pathway has become an important approach to current cancer therapy. Anti-VEGF therapy-related renal adverse effects may present as hypertension, non-nephrotic proteinuria, and rarely as nephrotic syndrome (NS) and acute kidney injury.